Últimas noticias sobre Alumis (NASDAQ:ALMS) Bolsa

ALUMIS INC

Alumis

Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.

wall street chart shutter2

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

ALMS

CMRX

DERM

Alumis, Chimerix y Journey Medical presentan altos valores RSI, lo que podría señalar sobrecompra. ¿Es este el momento adecuado para invertir?

¿Deberías preocuparnos por estas 3 acciones del sector salud? El RSI indica sobrecompra

Alumis Inc

Shares of gold-related equities, including Barrick Mining Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/B#NYSE">B</a>), U.S. Gold Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAU#NASDAQ">USAU</a>) and Newmont Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) are rallying on Monday as mounting trade tensions and geopolitical instability drive <a href="https://www.benzinga.com/crypto/25/06/45718471/michael-saylors-strategy-outperforms-apple-tesla-amazon-and-other-mag-7-stocks-and-its-not-even-close-has-the-bitcoin-treasury-bet-paid-off">investors toward safe-haven assets</a>.
What To Know: The SPDR Gold Trust ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) was up nearly 2.5% Monday afternoon as spot gold prices jumped to the highest levels in over three weeks. Spot gold climbed to $3,374.11 an ounce amid a weakening dollar and rising geopolitical and trade tensions, per Reuters.
U.S. President Donald Trump announced plans to double tariffs on steel and aluminum imports to 50% beginning June 4. The move triggered a renewed round of U.S.-China trade tensions, with Beijing vowing retaliation. This escalation, paired with Russia&#8217;s intensified military response to Ukrainian drone strikes over the weekend, pushed investors to exit risk assets and seek stability in precious metals. Spot silver was up over 4%, trading around $34.45 at last check.
The U.S. dollar index fell 0.5% to its lowest level in over a week, further supporting gold prices by making the metal more attractive to foreign buyers. As the dollar weakened and global risk sentiment deteriorated, investors appeared to rotate out of equities and into commodities in early trading Monday.
The sharp move higher in gold comes amid broader market volatility. While commodity-linked sectors outperformed, major U.S. indices struggled to gain ground as investors digested weak manufacturing data and anticipated key economic updates, including a U.S. jobs report and potential interest rate commentary from the Federal Reserve this week.
Price Action: At the time of publication Monday, Barrick Gold shares were up 5.77% at $20.26, U.S. Gold shares were up 6.61% at $12.33 and Newmont shares were up 5.25% at $55.49, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45728618/stocks-stall-commodities-rocket-as-trade-geopolitical-tensions-resume-whats-driving-market-monday">Stocks Stall, Commodities Rocket As Trade, Geopolitical Tensions Resume: What&#8217;s Driving Market Monday?</a></li>
</ul>
Image via Shutterstock.

Movers

USAU

Investors Are Buying Gold Stocks: What's Going On With Barrick Mining, US Gold And Newmont Shares Today?

Hyperfine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) stock is trading higher Monday after the company announced it secured clearance from the Food and Drug Administration (FDA) for its <a href="https://www.benzinga.com//node/45719228">new Swoop system</a>.
What To Know: The Swoop system is the&nbsp;first FDA-cleared AI-powered portable MRI system for the brain.
The company said the system delivers the highest level of image quality, functionality and usability to date. Hyperfine further stated that Optive AI software plays a central role in delivering faster, higher-quality scans.
&#8220;This next-generation hardware and the Optive AI&#x2122; software platform begin a new chapter for the adoption of AI-powered portable MRI. This clearance is the most significant innovation in the history of Hyperfine. We plan to launch the new Swoop&#xAE; system across hospital and office settings in the US, and we believe the new Swoop&#xAE; system performance will delight patients and providers, reduce the learning curve for users, and drive meaningfully faster adoption,&#8221; said Maria Sainz, President and CEO of Hyperfine.
The new Swoop system is being used in NEURO PMR, a Hyperfine-sponsored study examining the clinical utility of portable MRI in neurology offices. The two participating sites have reported very positive feedback from both users and patients so far.&nbsp;
See Also: <a href="https://www.benzinga.com/analyst-stock-ratings/upgrades/25/06/45728076/goldman-turns-bullish-on-saia-sees-room-for-shipping-efficiency-profit-growth">Goldman Turns Bullish On Saia, Sees Room For Shipping Efficiency, Profit Growth</a>
HYPR Price Action: At the time of writing, Hyperfine stock is trading 40.7% higher at 84 cents, according to data from <a href="https://pro.benzinga.com/">Benzinga Pro.</a>
Image: via Shutterstock

HYPR

Hyperfine Stock Is Soaring Higher Monday: What's Going On?

Telsey Advisory Group analyst Dana Telsey maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Outperform and maintains $385 price target.

Price Target

Analyst Ratings

LULU

Telsey Advisory Group Maintains Outperform on Lululemon Athletica, Maintains $385 Price Target

Telsey Advisory Group analyst Dana Telsey maintains Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) with a Market Perform and maintains $13 price target.

Telsey Advisory Group Maintains Market Perform on Guess, Maintains $13 Price Target

Experts commend the SEC's statement clarifying that protocol staking on proof-of-stake networks does not constitute securities, <a href="https://www.benzinga.com/news/legal/25/05/45471661/coinbase-under-sec-investigation-for-overstatement-of-user-numbers">fostering crypto innovation</a>.
What Happened: The Division of Corporation Finance's guidance <a href="https://www.sec.gov/newsroom/speeches-statements/statement-certain-protocol-staking-activities-052925">specifies</a> that staking activities on public, permissionless PoS networks, termed "Protocol Staking" are not investment contracts under the Howey test, as they lack entrepreneurial or managerial efforts from third parties.
Speaking with Benzinga, Kevin Liu, co-founder and CEO of GOAT Network, hailed the SEC's stance as a "welcome advancement" for the crypto industry. 
He noted that by recognizing rewards in protocol staking as derived from the protocol itself, not third-party efforts, the SEC provides critical clarity. 
This distinction, Liu emphasized, supports decentralized network innovation and benefits participants by establishing clear regulatory guidelines.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45729389/us-is-poised-to-become-global-crypto-hub-after-regulatory-breakthrough-binance-ceo-says">US Is Poised To Become Global Crypto Hub After Regulatory Breakthrough, Binance CEO Says</a>
The SEC's statement covers self-staking, self-custodial staking with third parties, and custodial arrangements, stating none meet the Howey test's "efforts of others" prong. 
Activities like slashing coverage, early unbonding and reward aggregation are deemed administrative, not managerial.
Experts see this as a signal that the U.S. is fostering a regulatory environment conducive to crypto growth, potentially positioning it as a global hub.
Experts view the guidance as a step toward balancing investor protection with innovation. 
By clarifying that protocol staking transactions do not require SEC registration, the decision reduces regulatory uncertainty, encouraging broader adoption of PoS networks like Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>).
The crypto industry anticipates this clarity will drive further development and investment in decentralized technologies.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45727395/tom-lee-predicts-bitcoin-to-hit-250000-by-end-of-2025-3m-long-term">Tom Lee Predicts Bitcoin To Hit $250,000 By End Of 2025, $3M Long Term</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

Expert Applauds SEC's Protocol Staking Clarity, Boosting Crypto Innovation

Telsey Advisory Group analyst Dana Telsey maintains Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) with a Market Perform and maintains $6 price target.

CURV

Telsey Advisory Group Maintains Market Perform on Torrid Holdings, Maintains $6 Price Target

Telsey Advisory Group analyst Dana Telsey maintains G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) with a Market Perform and maintains $30 price target.

GIII

Telsey Advisory Group Maintains Market Perform on G-III Apparel Group, Maintains $30 Price Target

Telsey Advisory Group analyst Dana Telsey maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Market Perform and maintains $24 price target.

VSCO

Telsey Advisory Group Maintains Market Perform on Victoria's Secret, Maintains $24 Price Target

Bank of America Securities analyst Jessica Reif Ehrlich maintained a Buy rating on Warner Bros. Discovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) with a <a href="https://www.benzinga.com/quote/WBD/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast of $14</a> on Monday.
Ehrlich argued, in an analyst report, that recent developments, notably an internal reorganization and an S&amp;P debt downgrade (viewed as an &#8220;ironically positive&#8221; event), have increased WBD&#8217;s strategic flexibility.
While acknowledging challenges, the analyst expressed continued belief in WBD&#8217;s compelling collection of assets and upcoming catalysts.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/entertainment/25/05/45327859/warner-bros-streaming-growth-cost-cuts-highlighted-analysts-stay-cautious" rel="noreferrer noopener">Warner Bros&#8217; Streaming Growth, Cost Cuts Highlighted, Analysts Stay Cautious</a>
The analyst said upcoming catalysts included easing Studio comparisons, potential recovery in advertising, further growth in direct-to-consumer (DTC), and exploring strategic options to drive shareholder value.
Following the merger of Discovery and WarnerMedia in early 2022 that created Warner Bros. Discovery (WBD), its shares have significantly underperformed the broader market and the analyst&#8217;s expectations.
Although several financial assumptions from the original merger have not materialized, the analyst reaffirmed her belief in the company&#8217;s unique and valuable underlying assets.
Ehrlich previously wrote that exploring strategic alternatives, such as a potential spin-off of the Studios and Streaming businesses, could be the most effective way to unlock the company&#8217;s significant unrecognized value.
The analyst noted that several developments in recent months have brought WBD closer to realizing opportunities for strategic alternatives.
Specifically, S&amp;P Global Ratings downgraded WBD&#8217;s debt on May 20 to BB+, a level below investment grade. The analyst views this as an &#8220;ironically positive&#8221; development for WBD&#8217;s equity, especially as the company navigates its onerous debt load.
Although WBD benefits from an extended debt maturity cycle at a low average coupon, a significant inhibiting factor for strategic actions was its two-pronged change of control covenant.
This covenant stipulated that both a change of control itself and a subsequent ratings downgrade to high yield were necessary for the debt to become callable.
However, with S&amp;P having already downgraded the debt to high yield, the analyst believes this &#8220;double-trigger&#8221; can no longer be tripped, thereby reducing the risks associated with pursuing strategic actions.
The analyst further detailed that in December, WBD announced a new corporate structure designed to enhance strategic flexibility and create potential opportunities to unlock shareholder value.
Under this reorganization, WBD now operates in two distinct divisions: Global Linear Networks and Streaming and Studios.
The analysts explained that Global Linear Networks will focus on maximizing profitability and free cash flow to continue deleveraging, while Streaming &amp; Studios will concentrate on driving growth and achieving strong returns on invested capital.
For 2025, Ehrlich projected WBD revenues of $38.2 billion and earnings per share of $1.63.
WBD&nbsp;Price Action: WBD stock is trading lower by 0.25% to $9.945 at&nbsp;last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/entertainment/25/05/45358172/paramounts-super-bowl-boost-and-studio-strength-help-offset-streaming-miss-analyst" target="_blank" rel="noreferrer noopener">Paramount&#8217;s Super Bowl Boost And Studio Strength Help Offset Streaming Miss: Analyst</a></li>
</ul>
Photo via Shutterstock

Reiteration

Warner Bros' Debt Downgrade Is An 'Ironically Positive' Event: Analyst

Per-ounce gold prices are up $1,000 from a year ago, and defensive-minded investors can be forgiven for balking at the yellow metal's skyrocketing price.
Metals experts cite multiple reasons why gold prices are so high right now.&nbsp;
"If you step back, it's not surprising that we've seen gold surge by $1,000 per ounce over the past year," said Rana Vig, president and CEO of Blue Lagoon Resources Inc., a Vancouver-based mineral exploration company. "It's a textbook gold rally created by a perfect storm of macroeconomic and geopolitical factors."
Vig said the economy and markets have seen persistent inflation concerns, aggressive central bank buying (especially from countries seeking to reduce U.S. dollar exposure), and ongoing global instability. "Add to that falling confidence in fiat currencies and tariff instability, and you have an environment where gold speculation can thrive."
Given gold&#8217;s rapid rise, investors who wish to use metals as a powerful hedge against volatile markets have other options.
It's worth noting that gold prices aren't necessarily out of reach for precious metals investors.
"No doubt, the easy money in this cycle may have already been made," Vig noted. "As for new investors coming in now, the upside will be harder to find without taking on more risk."
One major upside of gold is that it's not just a speculative asset or a hedge for volatility. In many parts of the world, it's a way of life. 
"In countries like India, where gold is deeply woven into the cultural and economic fabric, it's not uncommon for entire villages to pool resources and buy gold by the gram," Vig added. "Even the poorest households will save in gold, not stocks, not bonds because it's tangible, trusted, and borderless."
That level of generational trust in gold continues to anchor demand globally. "For Western investors, there's something to learn from that mindset: Gold isn't just about price, it's about preservation," Vig noted. "It's about holding something real when everything else feels uncertain."
<h2 class="wp-block-heading">Non-Physical Gold Portfolio Options</h2>
Experts say that if current per-ounce gold prices at $3,300 are too high, investors have formidable "Plan B" options in the precious metals market. These metal plays may be your best bets.
<h3 class="wp-block-heading">Silver</h3>
Silver&#8217;s price is expected to rise to $40 an ounce within the next six to twelve months, about a 20% increase from current levels.
"This is similar to the projection for gold, and silver and gold tend to move in tandem with each other," said Brett Elliott, marketing director at American Precious Metals Exchange in Urbandale, Iowa. "Silver has a constrained supply, large industrial buyers who will pay virtually any amount to get the silver they need, and growing demand from various sectors."
Additionally, silver rallies tend to follow gold rallies, and gold has been rallying frequently this year. "Just like gold, silver is highly liquid and can be bought and sold in physical form, through ETFs, or through digital silver apps where the metal is vaulted but owned by you," Elliot noted.
Another factor favoring silver is supply and demand.&nbsp;
"There's a huge silver shortage in the world due to a lack of silver mines, and the demand for silver will continue to be high due to its usage in electric vehicles, electric vertical take-off and landing vehicles, and other electrical appliances," said Sankar Sharma, investing analyst and founder of RiskRewardReturn.com, mentioning iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>). "The best and easiest way to invest in silver is via the iShares Silver Trust, which is trading at an attractive $29.99 entry price as of May 30."
<h3 class="wp-block-heading">Copper</h3>
Copper is another robust metal contender for defense-oriented investors. "It's essential electrification, whether it&#8217;s electric vehicles, grid infrastructure, or renewable power," Vig said. "And while copper's global demand is expected to outpace supply over the next decade, its market price, in many ways, still hasn't caught up relative to its fundamental story."
Geography also matters with copper.
"Copper is an excellent base metal to get into as electric utility needs for third world countries are only going to increase over the next 10 to 20 years," said Robert Kientz, operations lead at Kinesis Bullion USA.
Overall, global economies are moving into an expansion cycle, which should fuel demand for copper. "If an investor has a five-year game plan, then copper stocks and miners are likely to move higher," Sharma said.&nbsp;
Sharma added that good copper stocks to consider include Freeport McMoran (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>), Southern Copper Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>), Barrick Mining Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/B#NYSE">B</a>) and Rio Tinto Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIO#NYSE">RIO</a>).
<h3 class="wp-block-heading">Zinc</h3>
Zinc is an often overlooked precious metal, but it's critical to infrastructure across the globe. "As major economies reinvest in aging roads, bridges, and transport networks, zinc demand will remain strong," Vig said. "At the same time, recent supply disruptions have tightened the market, creating an attractive setup."
He recommends starting with producers like Teck Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TECK#NYSE">TECK</a>), which offers zinc and copper exposure in a single play. The stock is trading at $37 per share and is down over 8% for the year, suggesting a possible "buy the dip" opportunity.
<h3 class="wp-block-heading">Gold ETFs</h3>
Suppose you're only interested in exposure or short-term trades. In that case, a gold exchange-traded fund can provide a low-cost way of expanding your portfolio and has the added bonus of near-instant liquidity.
There are some caveats, however. "If you're planning to hold gold for a few years or longer, the expense ratio on most gold ETFs is cost inefficient in the long run," Elliot said. "Physical gold often provides a better value for gold longs. You pay the premium once on physical gold, but with an ETF, you pay the expense ratio every year."
It's also ideal to conduct thorough due diligence on gold ETFs.
"Before investing in gold funds, investors must review suitable ETFs to ensure the fund's holdings are purely linked to gold," Sharma said.
<h2 class="wp-block-heading">The Takeaway On Gold And Its Long-Term Outlook</h2>
Near the mid-point of 2025, gold is edging higher for two reasons.&nbsp;
"We are in a time of geopolitical instability and inflation of the monetary supply," said Blake Mclaughlin, vice president of exploration at Axcap Ventures. "With both scenarios at play, it's no surprise that we have seen the price of gold rise consistently over the last 18 months. Also driving the surge in price are the central banks' continuous and real-time adjustments in gold allocation."
Yet despite an uptick in the price, gold comprises just a fraction of a percent of global investment holdings, noted Mclaughlin. "However, with the release of the US Federal Reserve's May meeting minutes, which flagged rising inflation and risks of recession, gold's appeal as a safe-haven asset is likely to increase and may soon make up a larger portion of investor portfolios." 
That's what precious metals with limited capacity can do to drive a portfolio upward.&nbsp;
"When it comes to gold supply, a tap cannot be turned on to increase supply &#8211; it takes years, even decades, to substantially increase it, making a demand spike like the one we are seeing carry significant impacts," Mclaughlin added.
<h2 class="wp-block-heading">Rebound Or Breakdown? Join Matt Maley Live On Wednesday, June 4</h2>
The market is flashing major warning signs—tech is cracking, small caps are diverging, and rate pressure is building fast. Volatility is rising, and a sharp move could hit any day. Join 42-year Wall Street veteran Matt Maley as he breaks down the signals he's watching, the stocks he's targeting for short-term trades, and how he's positioning for the next major move—whether the market rips higher or breaks down next. Reserve your free spot <a href="https://events2.benzinga.com/matt-maley-webinar-wed-june4-2025-registration/?utm_campaign=webinar060425&amp;utm_adType=sponsorad&amp;utm_ad=RD060225&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_medium=newsletter">HERE</a>.
Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

SCCO

TECK

3 Gold Alternatives Set To Soar Next

<a href="https://www.bloomberg.com/news/articles/2025-06-02/supreme-court-seeks-doj-view-on-hertz-bondholder-case?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-02/supreme-court-seeks-doj-view-on-hertz-bondholder-case?embedded-checkout=true</a>

General

'Supreme Court Seeks DOJ View on Hertz Bondholder Case'- Bloomberg

Reuters Citing Draft Of Request Reports Trump Administration Wants Other Countries' 'Best Offer' By Wednesday In Tariff Talks

<a href="https://www.axios.com/2025/06/02/iran-nuclear-deal-proposal-enrich-uranium">https://www.axios.com/2025/06/02/iran-nuclear-deal-proposal-enrich-uranium</a>

'U.S. nuclear deal offer allows Iran to enrich uranium'- Axios

<ul>
<li>Two new partnerships enhance QIAGEN's capabilities to support pharma partner clinical trials with significant expansion of MRD capabilities – especially using QIAcuity digital PCR</li>
<li>Tracer Biotechnologies partnership to develop blood-based minimal residual disease (MRD) tests on QIAcuity digital PCR systems for solid cancer tumors</li>
<li>Collaboration with Foresight Diagnostics aims to develop a kit version of its CLARITY&#x2122; NGS assay for use in lymphoma</li>
</ul>
QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA))) today announced the expansion of its oncology diagnostics portfolio with two strategic partnerships to advance the use of minimal residual disease (MRD) testing in clinical trials to support pharma co-development projects for companion diagnostics. The new collaborations with Tracer Biotechnologies and Foresight Diagnostics expand QIAGEN's reach in MRD testing and cover solid tumors and hematological cancers.
Minimal residual disease (MRD) testing is becoming a cornerstone of oncology by enabling early detection of cancer recurrence and guiding timely adjustments to therapy from a blood sample. These new partnerships support the growing demand for decentralized, non-invasive tools that advance precision medicine and help deliver more personalized care.
Under the new collaborations:
<ul>
<li>Tracer Biotechnologies, a developer of blood-based molecular diagnostics for cancer, is working with QIAGEN to create companion diagnostics for MRD testing in solid tumors. These assays, designed for use on QIAGEN's QIAcuity digital PCR platform, are designed to enable the use of minimally invasive blood samples to monitor residual disease with high sensitivity. The approach offers a cost-efficient and quick way to support decentralized implementation in clinical laboratories with results comparable to those generated using next-generation sequencing technologies.</li>
<li>Foresight Diagnostics and QIAGEN are creating a kit-based version of the Foresight CLARITY&#x2122; assay, a circulating tumor DNA (ctDNA)-based NGS test for certain types of lymphoma. Transitioning the assay from a CLIA central laboratory service to an in-lab kit is designed to allow for broader clinical access and supports pharmaceutical-sponsored trials with companion diagnostic applications.</li>
</ul>
MRD testing offers a highly sensitive way to monitor treatment response, identify patients at risk of relapse before symptoms appear and inform decisions on therapy usage. It is also emerging as a surrogate endpoint in clinical trials, accelerating drug development and regulatory review.
QIAGEN's MRD portfolio spans sample technologies and testing platforms that support workflows from sample to insight. This includes the QIAsymphony system for automated sample preparation, with the new generation QIAsymphony Connect upgraded version being prepared for launch in late 2025, along with PAXgene blood collection tubes for stabilized blood draws. QIAGEN also offers an extensive range of kits for use on the QIAcuity family of digital PCR instruments as well as the QIAseq targeted gene panels for use on third-party NGS systems. Complementing these solutions is the portfolio of QIAGEN Digital Insights solutions that offer integrated bioinformatics for comprehensive NGS data analysis and interpretation to enable comprehensive MRD results.

QGEN

QIAGEN Expands Oncology Diagnostics Portfolio With Two Strategic Partnerships To Advance Use Of MRD Testing In Clinical Trials To Support Pharma Co-Development Projects For Companion Diagnostics

IBKR

Interactive Brokers Group Reports 3.384M Daily Average Revenue Trades In May, Up 43% From Last Year And 11% Lower Than Prior Month

Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares are trading lower Monday after the company announced it acquired an <a href="https://www.benzinga.com/pressreleases/25/06/g45724986/mullen-reaches-definitive-agreement-to-acquire-additional-21-of-bollinger-motors-bringing-its-tota">additional 21% of Bollinger Motors</a>.
What To Know: The additional stake brings the company&#8217;s total ownership in Bollinger to 95% and boosts shareholder equity by approximately $3.5 million.
&#8220;This is an important moment for both Mullen Automotive and Bollinger Motors,&#8221; said David Michery, CEO and chairman of Mullen Automotive and Bollinger Motors. &#8220;Our investment in acquiring the vast majority of remaining shares and resolving certain significant outstanding debt demonstrates our belief in and continued commitment to Bollinger&#8217;s vehicle lineup and future.&#8221;
Bollinger will continue developing and producing the B4 platform, its all-electric Class 4 commercial truck, leveraging Mullen's resources and expertise to accelerate progress and integrate into Mullen's broader EV ecosystem. Mullen may be facing selling pressure as the company had just $2.3 million in cash, cash equivalents and restricted cash as of March 31. 
Mullen also began trading on a split-adjusted basis on Monday after its 1-for-100 reverse stock split went into effect. The <a href="https://www.benzinga.com/news/stock-split/25/05/45679654/mullen-automotive-stock-is-tumbling-thursday-whats-driving-the-action">reverse stock split</a> was intended to bring the company into compliance with the Nasdaq's minimum bid listing requirements of $1 per share.
Related Link: <a href="https://www.benzinga.com/news/health-care/25/06/45724030/kymera-therapeutics-says-atopic-dermatitis-potential-matches-sanofi-regenerons-blockbuster-dupixent-in-early-biomarker-response">Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron&#8217;s Blockbuster Dupixent In Early Biomarker Response</a>
MULN Price Action: At the time of publication, Mullen shares were down 30.07% at $5.74, according to data from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Image: courtesy of Mullen Automotive.

MULN

Mullen Automotive Stock Is Falling Monday: What's Going On?

Circle Internet Financial is pushing forward with its public listing plans, now targeting a valuation of $7.2 billion as it gears up for an <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45622634/usdc-issuer-circle-eyes-600m-raise-in-nyse-ipo-targets-5-4b-valuation">initial public offering</a>.
What Happened: The company <a href="https://www.theblock.co/post/356602/circle-seeks-7-2-billion-valuation-in-upsized-ipo?utm_source=twitter&amp;utm_medium=social">announced</a> an increased offering size, reflecting heightened investor interest, with expectations of raising as much as $896 million through the sale of 32 million shares.
Originally, Circle intended to offer 24 million shares priced between $24 and $26. 
However, revised filings indicate the firm now aims to price its stock at $27 to $28 per share. 
This valuation remains below the $9 billion mark it was set to achieve in a previously abandoned SPAC deal in 2022. 
Despite this, major institutional players, most notably BlackRock (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NASDAQ">BLK</a>), are said to be backing the IPO.
Circle, best known as the issuer behind USD Coin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>), the world's second-largest stablecoin, has seen growing financial strength, especially through returns on U.S. Treasury holdings. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45727395/tom-lee-predicts-bitcoin-to-hit-250000-by-end-of-2025-3m-long-term">Tom Lee Predicts Bitcoin To Hit $250,000 By End Of 2025, $3M Long Term</a>
Why It Matters: In the first quarter of 2025 alone, Circle earned over $557 million from these assets, a 55% jump compared to previous periods.
Although it trails rival Tether (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>) in revenue, Circle has benefited from rising global interest in stablecoins, bolstered by clearer regulatory frameworks and increased real-world adoption. 
According to Standard Chartered, the market cap for stablecoins could expand tenfold by 2028. Similarly, a recent Artemis survey revealed that business-to-business stablecoin usage now accounts for the majority of stablecoin transaction volumes.
The company has secured approval to list on the New York Stock Exchange under the ticker symbol "CRCL," though a final listing date has yet to be confirmed. 
Plans to debut by April were delayed due to market instability tied to U.S. tariff policy debates. 
Despite reports of acquisition interest from Coinbase (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">COIN</a>) and Ripple (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), Circle has publicly denied pursuing any merger or acquisition deals at this time.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45722106/strategy-and-metaplanet-deepen-bitcoin-exposure-with-over-190-million-in-fresh-buys-amid-105k-market-level">Strategy And Metaplanet Deepen Bitcoin Exposure With Over $190 Million In Fresh Buys Amid $105K Market Level</a></li>
</ul>
Image: Shutterstock

$COIN

$USDC

$USDT

$XRP

USDC Issuer Circle Aims For $7.2B Initial Public Offering Valuation

Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) and NovoCure Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) revealed additional data on Saturday from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer.
The data were presented at <a href="https://www.benzinga.com/general/health-care">the 2025 American Society of Clinical Oncology Annual Meeting</a>.
The Phase 3 PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma compared to gemcitabine <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45710803/zai-lab-and-novocure-announce-results-from-the-phase-3-panova-3-trial-of-tumor-treating-fields-ttf" rel="noreferrer noopener">and nab-paclitaxel alone</a>.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/04/44988107/novocure-warns-of-potential-11-million-tariff-hit-if-us-trade-pause-expires-in-2025" target="_blank" rel="noreferrer noopener">NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025</a>
The trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) for patients <a href="https://www.benzinga.com/24/12/42268730/novocures-recently-approved-tumor-treating-electric-fields-shows-promise-in-pancreatic-cancer-patients" target="_blank" rel="noreferrer noopener">treated with TTFields</a>.
In the intent-to-treat population, patients treated with TTFields therapy concomitantly with gemcitabine and nab-paclitaxel had an mOS of 16.2 months compared to 14.2 months for patients treated with gemcitabine and nab-paclitaxel alone, a statistically significant 2.0-month improvement.
TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated improvement in several secondary endpoints, including one-year and pain-free survival rates.
The one-year survival rate showed a statistically significant improvement in the TTFields concomitant with gemcitabine and nab-paclitaxel treated group, 68.1%, compared to 60.2% for those who received gemcitabine and nab-paclitaxel alone.
Patients treated with TTFields concomitant with gemcitabine and nab-paclitaxel had a median pain-free survival of 15.2 months compared to a median of 9.1 months in the group treated with gemcitabine and nab-paclitaxel alone.
This is a statistically significant 6.1-month extension in pain-free survival. Pain-free survival was defined as the time from baseline until patients reported an increase of 20 or more points on a visual scale for pain or until death.
There was no statistically significant difference in additional secondary outcome measures of progression-free survival, local progression-free survival, objective response rate, puncture-free survival, or tumor resectability rate between the TTFields with gemcitabine and nab-paclitaxel and the gemcitabine and nab-paclitaxel arms.
TTFields therapy was well-tolerated, no new safety signals were observed, and safety was consistent with prior clinical studies. Mild to moderate skin adverse events (AEs) were the most common device-related AEs.
Price Action: NVCR stock is trading lower by 8.63% to $17.46 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45726138/dell-stock-falls-as-trump-administration-expands-spending-review-to-tech-contracts" target="_blank" rel="noreferrer noopener">Dell Stock Falls As Trump Administration Expands Spending Review To Tech Contracts</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Biotech

Health Care

NVCR

ZLAB

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

Morgan Stanley analyst Adrienne Yih maintains American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) with a Equal-Weight and lowers the price target from $11 to $10.

Morgan Stanley Maintains Equal-Weight on American Eagle Outfitters, Lowers Price Target to $10

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Harmony Biosciences Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRMY#NASDAQ">HRMY</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $52.11, a high estimate of $70.00, and a low estimate of $44.00. This current average has increased by 1.94% from the previous average price target of $51.12. 
<img src="https://www.benzinga.com/files/images/story/2025/1748887265_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive Harmony Biosciences Hldgs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andreas Argyrides</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$61.00</td>
<td>-</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$48.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$49.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$49.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$44.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Harmony Biosciences Hldgs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Harmony Biosciences Hldgs compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Harmony Biosciences Hldgs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Harmony Biosciences Hldgs's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HRMY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Harmony Biosciences Hldgs analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Harmony Biosciences Hldgs</h2>
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
<h3>Harmony Biosciences Hldgs: Financial Performance Dissected</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Harmony Biosciences Hldgs's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 19.48% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Harmony Biosciences Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 24.66% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Harmony Biosciences Hldgs's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.6%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Harmony Biosciences Hldgs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.43% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Harmony Biosciences Hldgs's debt-to-equity ratio is below the industry average. With a ratio of 0.24, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HRMY

Where Harmony Biosciences Hldgs Stands With Analysts

Press Releases

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote "FOR" the Proposed Transaction with Alumis

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Stockholders Approve Merger with ACELYRIN

Earnings

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Completes Merger with ACELYRIN

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Comments

Alumis

Noticias

Últimas noticias sobre Alumis (NASDAQ:ALMS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL